Want to see RNXT full AI Analyst Report?
Top Page
RenovoRx
(NASDAQ:RNXT)
Select Model
Select Model
Rating:58Neutral
Price Target:
$1.50
▲(5.63% Upside)
Action:Reiterated
Date:09/11/26
RNXT scores as moderate overall, led by improving technical momentum and a generally upbeat earnings update (raised revenue guidance, strong gross margins, expanding commercial footprint). The score is held back primarily by weak financial performance—large ongoing losses and significant negative free cash flow—and valuation limitations from a negative P/E and no dividend support. Corporate events modestly help via regained Nasdaq compliance but recent listing-risk history remains a consideration.
Positive Factors
Rapid commercial expansion and revenue growth
Rapid revenue growth alongside expanding commercial-center adoption indicates that RenovoRx is converting its platform into recurring clinical use. A larger installed base and growing site funnel can support durable revenue expansion as repeat procedures and new activations compound.
Negative Factors
Large ongoing losses and persistent cash burn
The company is not yet self-financing: substantial operating and free-cash-flow deficits require continued use of cash or external capital. Persistent losses can constrain investment flexibility and may pressure the business to raise funding before reaching sustainable operating scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid commercial expansion and revenue growth
Rapid revenue growth alongside expanding commercial-center adoption indicates that RenovoRx is converting its platform into recurring clinical use. A larger installed base and growing site funnel can support durable revenue expansion as repeat procedures and new activations compound.
Read all positive factors
RenovoRx (RNXT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$76.27M
Dividend YieldN/A
Average Volume (3M)1.20M
Price to Earnings (P/E)―
Beta (1Y)0.88
Revenue Growth198.49%
EPS Growth16.29%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.32
Shares Outstanding45,129,510
10 Day Avg. Volume959,927
30 Day Avg. Volume1,201,845
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)5.47
Price to Sales (P/S)26.43
P/FCF Ratio-2.70
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.13Price Target Upside401.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$3.65M
RenovoRx Business Overview & Revenue Model
Company Description
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-a...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, RenovoRx has not established a mature, recurring commercial revenue base from product sales; publicly available information indicates it is primarily in the research and development phase, advancing i...
RenovoRx Earnings Call Summary
Earnings Call Date:Aug 12, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Positive
The call presented substantial commercial and clinical progress: record revenue with strong sequential and year-over-year growth, expanding active sites and a robust pipeline, completion of phase 3 enrollment, high gross margins, and improving adjusted operating loss. Key risks highlighted include continued operating losses and high SG&A relative to current revenue, declining cash to $9.5M and dependence on rapid site conversions and remaining clinical events to achieve the projected revenue run rate and breakeven timeline. On balance, the call conveyed positive execution and momentum with identifiable near-term operational and timing risks.Positive Updates
Record Quarterly Revenue
Second quarter 2026 revenue of $909,000, the strongest quarter to date, up ~61% sequentially from $563,000 and up ~115% year-over-year from $422,000. Q2 revenue represented ~83% of full-year 2025 revenue ($1.1M).
Negative Updates
Continued Operating Losses and Elevated SG&A
Loss from operations remained ~ $3.4M for the quarter and selling, general & administrative expenses were elevated at ~$2.9M, which is large relative to current revenue levels.
Read all updates
Q2-2026 Updates
Positive
Negative
Record Quarterly Revenue
Second quarter 2026 revenue of $909,000, the strongest quarter to date, up ~61% sequentially from $563,000 and up ~115% year-over-year from $422,000. Q2 revenue represented ~83% of full-year 2025 revenue ($1.1M).
Read all positive updates
Company Guidance
RenovoRx tightened full‑year 2026 revenue guidance to $3.75–$4.25M (up from $3.0–$4.0M), implying 241–286% YoY growth vs $1.1M in 2025, and said it is progressing toward a ~$5M quarterly revenue run rate needed for cash‑flow breakeven (targeted Q4 2027). At 6/30/2026 cash was $9.5M (down from $12.4M at 3/31/26), which management expects provides runway into H2 2027; they remain opportunistic on capital but focused on revenue. Commercial KPIs: 21 active commercial centers at quarter end, a target of ≥36 by year‑end, 42 additional centers in process for a 63‑center funnel (a 31% increase vs 48 in Q1), and 15 TIGeR‑PaC sites positioned to transition to commercial use. Q2 results underpin the guidance: revenue $909K (up ~61% sequential from $563K and ~115% YoY from $422K; Q2 revenue ≈83% of 2025 total), gross profit $706K (~84% gross margin), R&D ≈$200K, SG&A ≈$2.9M, loss from operations ≈$3.4M, and net loss per share improved to $0.06. Finally, Phase 3 TIGeR‑PaC is fully enrolled, requires 86 events for completion (78 events as of 8/11/2026), with initial topline data expected in H2 2027.RenovoRx Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
29
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.98M | 1.12M | 43.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.67M | 796.00K | 43.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -12.29M | -11.17M | -8.81M | -10.12M | -9.83M | -5.48M |
| Net Income | -12.29M | -11.17M | -8.81M | -10.23M | -9.89M | -6.32M |
Balance Sheet | ||||||
| Total Assets | 11.47M | 8.10M | 8.12M | 1.47M | 7.26M | 16.29M |
| Cash, Cash Equivalents and Short-Term Investments | 9.48M | 7.02M | 7.15M | 1.17M | 6.44M | 15.19M |
| Total Debt | 259.00K | 212.00K | 278.00K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.49M | 2.67M | 3.64M | 4.47M | 1.10M | 938.00K |
| Stockholders Equity | 8.98M | 5.42M | 4.48M | -3.00M | 6.16M | 15.35M |
Cash Flow | ||||||
| Free Cash Flow | -11.94M | -10.97M | -9.14M | -10.26M | -8.81M | -5.93M |
| Operating Cash Flow | -11.87M | -10.97M | -9.13M | -10.26M | -8.81M | -5.92M |
| Investing Cash Flow | -71.00K | -2.00K | -12.00K | 2.03M | -2.03M | -15.00K |
| Financing Cash Flow | 9.10M | 10.85M | 15.12M | 5.01M | 42.00K | 19.33M |
RenovoRx Technical Analysis
Positive
1.42
Price Trends
1.34
Positive
1.11
Positive
1.03
Positive
Market Momentum
0.11
Positive
51.16
Neutral
11.94
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNXT, the sentiment is Positive. The current price of 1.42 is below the 20-day moving average (MA) of 1.80, above the 50-day MA of 1.34, and above the 200-day MA of 1.03, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 51.16 is Neutral, neither overbought nor oversold. The STOCH value of 11.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RNXT.
RenovoRx Risk Analysis
RenovoRx disclosed 73 risk factors in its most recent earnings report. RenovoRx reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
RenovoRx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $76.27M | -5.34 | -145.63% | ― | 198.49% | 16.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $60.08M | -6.13 | -50.77% | ― | 327.25% | 85.65% | |
44 Neutral | $40.00M | -0.71 | -98.86% | ― | ― | -33.92% | |
42 Neutral | $42.64M | -0.08 | 77.63% | ― | 6.81% | 11.95% | |
42 Neutral | $26.92M | -0.51 | -144.24% | ― | -19.76% | 8.58% | |
41 Neutral | $21.14M | -0.34 | -108.72% | ― | 2.15% | 17.34% |
* Healthcare Sector Average
RNXT
RenovoRx
1.69
0.39
30.00%
IMMP
Immutep
0.29
-1.42
-83.22%
KPTI
Karyopharm Therapeutics
1.88
-3.97
-67.86%
TCRX
TScan Therapeutics
0.31
-1.47
-82.53%
XLO
Xilio Therapeutics
9.13
-1.58
-14.75%
RADX
Radiopharm Theranostics Limited Sponsored ADR
1.65
-4.40
-72.73%
RenovoRx Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
RenovoRx Regains Nasdaq Compliance on Minimum Bid Price
Positive
Aug 20, 2026
On December 31, 2025, RenovoRx, Inc. received notice from Nasdaq that it was not in compliance with the exchange’s minimum bid price rule because its common stock had closed below $1.00 per share for 30 consecutive business days. This noncom...
Business Operations and StrategyProduct-Related Announcements
RenovoRx Highlights TAMP Platform in Upcoming Oncology Webinar
Positive
Aug 4, 2026
On August 4, 2026, RenovoRx announced it would participate in a JonesTrading key opinion leader webinar on August 13, 2026, focused on the evolving pancreatic cancer treatment landscape and its TAMP platform. The event will feature oncology specia...
Delistings and Listing ChangesRegulatory Filings and Compliance
RenovoRx Granted Extended Nasdaq Compliance Period Amid Listing Risk
Negative
Jul 2, 2026
On December 31, 2025, RenovoRx received a deficiency notice from Nasdaq stating that its common stock had fallen below the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market. The company was initially given until J...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
RenovoRx Stockholders Approve Directors and Equity Plan
Positive
Jun 30, 2026
On June 30, 2026, RenovoRx, Inc. held its 2026 annual meeting of stockholders, where approximately 22,825,465 voting shares were present or represented by proxy, constituting a quorum for corporate action. Stockholders elected seven directors, inc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.